137 related articles for article (PubMed ID: 35467243)
21. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
22. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
23. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
25. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.
Infante JR; Dees EC; Olszanski AJ; Dhuria SV; Sen S; Cameron S; Cohen RB
J Clin Oncol; 2014 Oct; 32(28):3103-10. PubMed ID: 25113756
[TBL] [Abstract][Full Text] [Related]
26. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
27. A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.
Halford S; Veal GJ; Wedge SR; Payne GS; Bacon CM; Sloan P; Dragoni I; Heinzmann K; Potter S; Salisbury BM; Chénard-Poirier M; Greystoke A; Howell EC; Innes WA; Morris K; Plummer C; Rata M; Petrides G; Keun HC; Banerji U; Plummer R
Clin Cancer Res; 2023 Apr; 29(8):1429-1439. PubMed ID: 36652553
[TBL] [Abstract][Full Text] [Related]
28. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
[TBL] [Abstract][Full Text] [Related]
29. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Dowlati A; Harvey RD; Carvajal RD; Hamid O; Klempner SJ; Kauh JSW; Peterson DA; Yu D; Chapman SC; Szpurka AM; Carlsen M; Quinlan T; Wesolowski R
Invest New Drugs; 2021 Aug; 39(4):1057-1071. PubMed ID: 33624233
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
32. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
Pant S; Burris HA; Moore K; Bendell JC; Kurkjian C; Jones SF; Moreno O; Kuhn JG; McMeekin S; Infante JR
Invest New Drugs; 2014 Feb; 32(1):87-93. PubMed ID: 23525756
[TBL] [Abstract][Full Text] [Related]
33. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
[TBL] [Abstract][Full Text] [Related]
34. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
[TBL] [Abstract][Full Text] [Related]
35. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
36. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
Doi T; Onozawa Y; Fuse N; Yoshino T; Yamazaki K; Watanabe J; Akimov M; Robson M; Boku N; Ohtsu A
Cancer Chemother Pharmacol; 2014 Sep; 74(3):629-36. PubMed ID: 25059319
[TBL] [Abstract][Full Text] [Related]
37. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
Hong DS; Hui D; Bruera E; Janku F; Naing A; Falchook GS; Piha-Paul S; Wheler JJ; Fu S; Tsimberidou AM; Stecher M; Mohanty P; Simard J; Kurzrock R
Lancet Oncol; 2014 May; 15(6):656-66. PubMed ID: 24746841
[TBL] [Abstract][Full Text] [Related]
38. First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.
Schöffski P; Awada A; de la Bigne AM; Felloussi Z; Burbridge M; Cantero F; Colombo R; Maruzzelli S; Ammattatelli K; de Jonge M; Aftimos P; Dumez H; Sleijfer S
Eur J Cancer; 2022 Jul; 169():135-145. PubMed ID: 35567919
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
40. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
